Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FoldRx Pharmaceuticals
Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.
F-Prime Plays The Long Game In Health Care Investing
With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.
Orphans Should Live Alone
For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.